Experiences with IL-1 blockade in systemic juvenile idiopathic arthritis - data from the German AID-registry.
Elke LainkaMelanie BaehrBernadette RaszkaJohannes-Peter HaasBoris HügleNadine FischerDirk FoellClaas HinzeElisabeth Weissbarth-RiedelTilmann KallinichGerd HorneffDaniel WindschallEggert LilienthalTim NiehuesUlrich NeudorfRainer BerendesRolf-Michael KüsterPrasad Thomas OommenChristoph RietschelThomas LutzFrank Weller-HeinemannKlaus TenbrockGeorg Leonhard HeubnerJens KlotscheHelmut WittkowskiPublished in: Pediatric rheumatology online journal (2021)
In a large cohort of sJIA patients from Germany, we can confirm an overall favorable clinical response to both available IL-1 blocking agents. IL-1i was well tolerated with acceptable safety and effectiveness in a real-life clinical setting.